Understanding the Results

Knowing your Class can be extremely helpful to you and your doctor

umdx_logoDecisionDx™-UM measures the activity of 15 specific genes within your eye tumor to determine the likelihood of it spreading from the eye. The test identifies your prognosis as either  Class 1A, Class 1B or Class 2, which represents the statistical risk of metastasis over five years, the period for which data has been collected.

This information can be extremely helpful to you and your doctor in planning your follow-up care. There are considerations about the kind and frequency of monitoring you will need, and whether you would be a candidate for certain treatments or even clinical trials as they become available.

Below are the potential test results, and the considerations for each:

Class 1A
These patients are at a very low risk of metastasis, with just a 2% chance of the eye cancer spreading over the next five years. Your doctor may recommend a less frequent monitoring program which might include bloodwork, office visit(s) and/or imaging such as X-ray, ultrasound, CT/PET or MRI.

Class 1B
These patients have a slightly higher risk of metastasis than those in Class 1A, or 21% over the next five years, but overall, are still considered low risk. However, to be on the safe side, your doctor may choose to monitor you more closely.

Class 2
These patients are at high risk, with 72% risk of metastasis over the next five years.

If you have a Class 2 tumor, your doctor may recommend a high intensity program to monitor you for evidence of metastasis. This might include quarterly MRI or CT scans, along with quarterly liver function tests. Your doctor may also recommend referral to a medical oncologist for preventive treatment, and to review clinical trial opportunities. Results from molecular testing such as DecisionDx-UM will help determine whether or not you might qualify for such trials as they become available.

While the DecisionDx-UM test cannot, at this point, guide your doctor toward a specific therapy like chemotherapy, a recent study published in Clinical Ophthalmology, which involved doctor surveys and medical chart review of Medicare-treated patients, showed that molecular testing such as the GEP test has a significant impact on the management of uveal melanoma. Not only are most ophthalmologists treating uveal melanoma using molecular testing, but they are also more likely to increase frequency of disease monitoring or recommend clinical trials for those patients whose test results showed they were at high risk of metastasis.

Decisions about your surveillance, treatment and other follow-up plans should be made by you and your doctors.


Know your TYPE, Know your RISK
You’ve just been diagnosed with uveal melanoma, and it’s important to know that there is a test that can identify your tumor type—and the risk of your cancer spreading.

GETTING TESTED       Timing is Critical
To know your tumor type and risk, a biopsy must be taken BEFORE radiation treatment.

Talk to                 Your Doctor
Use this discussion guide to talk to your doctor about the genomic test to learn your tumor type, or CLASS.


Sign Up For Updates

Please leave this field empty.

Share on Facebook+1Share on Twitter

Share Your Stories

There's comfort in knowing you are not alone. If you or a loved one have experienced uveal melanoma and would like to help encourage others whose lives have been touched by this disease, please share your story with us.
Start Sharing